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LB2392 The structure of the cell wall polysaccharide of
Enterococcus faecalis is critical for evasion of complement
deposition by the lectin pathway
C. Theilacker °, S. Geiss, P. Sanchez-Carballo, O. Holst, J.A. van
Strijp, J. Hu¨bner, S. Rooijakkers (Freiburg, Borstel, DE; Utrecht, NL)
Objective: Enterococcus faecalis is a Gram-positive pathogen that may
cause invasive infections in immunocompromised patients. E. faecalis is
resistant to serum but the molecular mechanism underlying complement
evasion is not known. The mechanism of increased serum sensitivity
of an insertion mutant of the putative glycosyltransferase EF1172 in
E. faecalis strain V583 was investigated.
Methods: Complement deposition and phagocytosis was quantiﬁed by
FACS. Killing of enterococci in the presence of serum and PMNs was
measured using an opsonophagocytic killing assay. Human pooled serum
was preabsorbed with live wild-type E. faecalis V583 for all assays.
Structural polysaccharide analysis was performed by gas chromatography
and NMR spectroscopy.
Results: Incubation of E. faecalis V583Delta1172 with 1.5% serum
and PMNs for 90 min reduced the number of viable bacteria by
>2 logs, while wild type bacteria were resistant to killing under
these experimental conditions. After 15 min incubation of live bacteria
preopsonized with human pooled serum (HPS), PMNs phagocytosed
ﬁvefold more E. faecalis V583Delta1172 than wild type bacteria. Also,
signiﬁcantly more C3b was deposited on V583Delta1172 compared to
the wild type strain. Measurement of C3b deposition by serum depleted
of complement factor C1q or Ca++ excluded a role of the classical
and alternative pathway of complement activation by the mutant strain.
Furthermore, V583Delta1172 incubation with HPS lead to more binding
of C4b – a component of the C3 convertase generated by the classical
and lectin pathway – than wild type cells. The role of the lectin pathway
in increased susceptibility to complement was conﬁrmed by elevated
levels of mannose binding lectin-associated serum protease 2 (MASP-2)
bound to the mutant strain. Biochemical characterization of the cell wall
polysaccharide of V583Delta1172 revealed an altered composition with
a loss of galactosamine, a increased ratio of rhamnose:glucose (~2:1 in
E. faecalis V583 wild type, ~4:1 in V583Delta1172) and lower phosphate
content compared to the wild type strain.
Conclusion: The structure of the wall polysaccharide of E. faecalis
is critical for resistance to complement activation by the lectin
pathway, possibly by altered charge or three-dimensional structure of
the polysaccharide.
LB2393 Different erythromycin-resistant phenotypes of
Streptococcus pyogenes do not prevent human
polymorphonuclear cells from their antibacterial activity
G. Banche, V. Tullio, V. Allizond, N. Mandras, J. Roana, D. Scalas,
F. El Fassi, S. D’Antico °, N. Carlone, A.M. Cufﬁni (Turin, Italy, IT)
Objectives: Albeit the prevalence of macrolide resistance in Streptococ-
cus pyogenes reported by several countries has signiﬁcantly increased,
these alarming in vitro results not always demonstrate a relationship
with an in vivo negative impact on clinical efﬁcacy, since the standard
susceptibility testing methods do not take into account several host’s
defense mechanisms, that play a key role during infection in preventing
the triggering and spreading of a bacterial infection process. In order to
evaluate the potential immunomodulatory activity of erythromycin upon
the binomial antibiotic-resistant bacterium/host, the PMN phagocytic
and bactericidal activities against streptococcal strains Ery-S and Ery-R
belonging to different phenotypes were assessed in the presence of the
macrolide.
Methods: The erythromycin-resistance phenotypes of S. pyogenes were
determined by the triple-disk diffusion testing. Polymorphonuclear cells
(PMNs) were separated from lithium heparinized venous blood pooled
from healthy donors, negative for the presence of microbial diseases,
by using Ficoll–Paque. The effects of erythromycin on either the
phagocytosis of radiolabelled S. pyogenes [3H-uracil (speciﬁc activity:
1.27 TBq/mmol; NEN Products, Milan, Italy)] or intracellular bacterial
killing by PMNs were investigated by incubating the bacteria and the
phagocytes (bacterium:PMN ratio was 10:1) at 37ºC for various periods
in the presence of the MIC of the drug. Erythromycin-free controls were
also included.
Results: Our results showed that when erythromycin, PMNs and
streptococci, both Ery-S and Ery-R (cMLSB, M, iMLSB-A, -B, -C
phenotypes), were present in the culture medium, the phagocytic activity
of PMNs overlapped that of controls without drug. In contrast, the results
emphasized a signiﬁcant high increase of intracellular killing by PMNs
in the presence of erythromycin for Ery-S and Ery-R S. pyogenes, with
high (cMLSB, iMLSB-A and iMLSB-B phenotypes) and moderate (M
and iMLSB-C phenotypes) level of Ery-resistance compared to controls
without drug.
Conclusion: These results indicate that erythromycin has a signiﬁcant
immunomodulating activity on host-bacterium interaction being able to
determine a signiﬁcant increase of microbicidal activity in human PMNs
against all S. pyogenes strains, either Ery-S or Ery-R, with high and
moderate resistant level, conﬁrming that the antibiotic resistance detected
in vitro does not always imply a failure of antimicrobial treatment.
LB2394 Three simple ESCMID severity criteria predict poor cure
rate and slower resolution of diarrhea in Clostridium
difﬁcile infection
M.A. Miller °, E.J. Kuijper, D.N. Gerding, S. Gorbach (Montreal,
CA; Leiden, NL; Chicago, Boston, US)
Objectives: The European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) has recently published a Clostridium
Difﬁcile Infection (CDI) “treatment guidance document”. Of their 14
severity criteria, 3 had been routinely collected in a recently-completed
phase 3 randomized clinical trial (RCT) of ﬁdaxomicin vs vancomycin in
the treatment of CDI. We examined the prevalence of these 3 criteria and
their relationship to cure, recurrence, global cure and time to resolution
of diarrhea (TTROD).
Methods: The only 3 ESCMID severity criteria which had been collected
routinely and could be used were: temperature, leukocyte count, and
acutely elevated serum creatinine. They were available in all subjects in
the “modiﬁed Intent to Treat” (mIT) group analysis (n = 596). Baseline
serum creatinine was not available so the surrogate of initial creatinine
1.5mg/dL was used instead. Per ESCMID guidelines, patients with
1 criteria could be classiﬁed as severe CDI. Standard deﬁnitions of
cure were applied. Global cure = initial cure without recurrence. TTROD
was counted from onset of treatment to 3 unformed bowel movements.
Analyses were performed on mITT subjects; the “Per Protocol” group
analyses were very similar. The 2 treatment groups were combined for
this analysis.
Results: 155 subjects (26%) had 1 of the 3 severity criteria (“severe
group”): 8 (1.3%) with T> 38.5ºC; 84 (14.1%) with WBC >15×109/L;
and 86 (14.4%) with creatinine >1.5mg/dL. The cure rate for severe
cases (77%) was lower than for non-severe cases (90%) (P< 0.001).
Recurrence rates were not statistically different in the 2 groups. Median
S718 20th ECCMID, Late Breaking News
TTROD was longer in the severe group compared to the non-severe
group (103 h vs 59 h, respectively; P = 0.002).
Conclusions: To serve as a useful tool, a severity score should be easy
to use and correlate with outcomes. In the ﬁdaxo vs. vanco RCT, 26%
of subjects could be classiﬁed as severe by 3 simple ESCMID criteria.
The classiﬁcation of severe was signiﬁcantly correlated with a lower
cure rate at end of therapy and with prolonged TTROD. These 3 simple
severity markers were useful in predicting clinical outcomes of CDI.
If such criteria are validated prospectively, they may prove invaluable
for categorizing patients in RCTs of CDI and for guiding therapy in
individual CDI patients.
LB2395 Identiﬁcation of common fungal pathogens in a single
sample
K.M. McCarney °, K. Dempsey, J. Redden, A. Ricketts, W. Ewen Smith,
P. Lewis White, M.D. Perry, R.A. Barnes (Glasgow, Cardiff, UK)
Objectives: The objective was to develop a highly sensitive and speciﬁc
single test for the direct detection of Aspergillus and Candida species
within clinical specimens.
Methods: Surface enhanced resonance Raman scattering (SERRS)
allows more analytes to be detected at lower concentration than
ﬂuorescence. Multiplex assays were developed to detect a broad range
of pathogenic fungal species, present in clinical samples, in low copy
number. Genus speciﬁc polymerase chain reaction (PCR) primers and
species speciﬁc probes were designed to detect multiple targets from
spiked serum/whole blood samples. Each probe has a unique spectrum
allowing identiﬁcation of multiple targets in a mixture. One primer
from each set was modiﬁed with biotin to capture ampliﬁed DNA on
microbeads. The speciﬁc probes were hybridised to the PCR products
and captured on microbeads. The probe is released from the microbeads
and analysed by SERRS for rapid detection of multiple pathogenic fungal
targets.
Results: The assay was tested successfully against blind panels and is
capable of detecting most clinically relevant species of Candida and
Aspergillus. It is designed to differentiate azole resistant species and
can detect multiple aetiologies in one specimen. The detection limit is
2−3 copies input per reaction and can reproducibly detect 101 organisms
within a simulated clinical specimen.
Conclusions: In this preliminary study, the assay successfully identiﬁes
the most common fungal pathogens with high efﬁciency and demon-
strates sensitivity down to 2−3 PCR input copies. This assay is ready
to go into pre-clinical testing with the addition of software designed
to automate the analysis and the detection range will be increased
to cover additional fungal agents. This is the ﬁrst clinical application
developed using D3 Technologies’ powerful detection platform. The
ﬂexibility of this technology will enable ready adaptation to other clinical
applications.
LB2396 Direct detection of triazole resistance in A. fumigatus
from airway secretions
S. Park, M. Fraczek, M. Kirwan, S.A. Follett, K. Radej, A. Moody,
D.S. Perlin, D.W. Denning ° (Newark, US; Manchester, UK)
Objectives: Aspergillus fumigatus causes signiﬁcant morbidity in
immunocompromised patients, asthma, cystic ﬁbrosis and chronic
pulmonary aspergillosis (CPA). Culture positive rates in invasive disease
and CPA are typically ~30%. Rates of culture positivity in allergic
aspergillosis (ABPA) are typically ~60%. Increasing rates of azole
resistance, determined by MIC on positive cultures, have been noted
since 2004. Culture negative cases do not currently allow susceptibility
to be determined.
Methods: Patients were recruited from the National Aspergillosis
Centre, Manchester if they provided a fresh sputum sample. Samples
were split for microscopy and fungal culture or PCR. DNA extraction
was performed with the MycXtra kit and real-time PCR using the
MycAssay Aspergillus assay. Only those samples that were PCR positive,
culture negative were subjected to a nested PCR approach. The CYP51A
gene was ampliﬁed using Invitrogen Platinum Taq polymerase in two
fragments. Fragment 1 (876 bp) covered the promoter tandem repeat
region to codon 98. The second amplicon (748 bp) covered codons
54 to 266. PCR products were cleaned up and each was used as
a template to probe with molecular beacon assays for known azole
resistance SNPs.
Results: 30 patients were PCR positive and culture negative for
Aspergillus species. No G54 or M138 mutations were found. Four
samples had M220 mutations. Sixteen of 29 (52%) had both a tandem
repeat (TR) with an H98L mutation. Of particular interest, two samples
had a M220 mutation with a TR+ H98L mutation and the TR was found
without the H98L mutation in 3 and the H98L mutation without the
tandem repeat in 2. One sample did not amplify fragment 2. Overall,
therefore 18 of 30 (60%) samples had evidence of azole resistance.
Amongst these patients, 6/8 (75%) had ABPA, 11/20 (55%) had CPA and
1/2 (50%) had bronchiectasis with documented aspergillosis. Four had
never received triazole therapy and two had known pan-azole resistant
CPA (M220K and unknown mechanism). Four were taking itraconazole
(2 clearly failing Rx, one non-compliant, one worsening after response,
three were taking voriconazole (2 clearly failed Rx, one stable with
toxicity) and 5 were taking posaconazole (3 responders, 2 primary Rx).
Conclusions: Using a commercial real-time assay for Aspergillus,
residual DNA can be used directly to determine azole resistance in
A. fumigatus. In this small single centre sample, it would appear that
resistance is common.
LB2397 C-reactive protein serum levels as an early predictor of
outcome in patients with pandemic H1N1 inﬂuenza A
virus infection
O. Zimmerman °, O. Rogowski, G. Aviram, M. Mizrahi, D. Zeltser,
D. Justo, E. Dahan, R. Arad, O. Touvia, L. Tau, J. Tarabeia, S. Berliner,
Y. Paran (Tel Aviv, IL)
Objective: To retrospectively examine whether the admission serum
C-reactive protein (CRP) levels of patients with pandemic inﬂuenza A
(H1N1) infection can serve as a predictor of illness severity.
Methods: Included were consecutive adult patients who presented to
our emergency department (ED) between May and December 2009,
with a ﬂu-like illness, a conﬁrmed diagnosis of pandemic inﬂuenza A
(H1N1) infection and a serum CRP level that was measured within
24 hours of presentation. Patients with a proven additional concurrent
acute illness were excluded. Outcome measures were intensive care unit
(ICU) admission, initiation of mechanical ventilation and death.
Results: Seventeen of the 191 enrolled patients (9%) were admitted
to the ICU, of whom eight required mechanical ventilation and three
died. The median admission serum CRP levels were signiﬁcantly higher
among patients who subsequently required ICU care and those who
required mechanical ventilation compared to patients who did not
(123 vs. 40mg/L, p< 0.001 and 112 vs. 43mg/L, p = .017, respectively).
Admission serum CRP level and auscultatory ﬁnding over the lungs
(bronchial breath sounds or crackles) were independent prognostic
factors for the need of ICU care. The CRP hazard ratio (95%CI) for
being transferred to the ICU was 1.09 (1.06–1.12) for each increase
of 10mg/L in CRP level. The admission serum CRP level was the
only independent prognostic factor for mechanical ventilation. The CRP
hazard ratio (95%CI) for mechanical ventilation was 1.09 (1.05–1.13)
for each increase of 10mg/L in CRP level.
A Kaplan–Meier estimate of the two outcome measures, i.e., the need
for ICU admission and for mechanical ventilation, was performed using
tertiles of serum CRP levels (i.e., <28, 28−69 and 70mg/L). At the
30-day time point since their presentation to the ED, none of the patients
with a serum CRP level <28mg/L needed to be admitted to the ICU
or required mechanical ventilation (Figure 1). At the same time point,
19% of the patients with a serum CRP level 70mg/L needed to
be admitted to the ICU and 8% required mechanical ventilation. The
differences in the rates between the lower vs. upper tertile groups were
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signiﬁcant (Log-Rank p< 0.001 for ICU and p< 0.024 for mechanical
ventilation).
Conclusions: Serum CRP levels in patients with pandemic H1N1 in-
ﬂuenza A infection can serve as a useful measurement to predict disease
course and assist in patient management as early as ED admission.
Figure 1. Kaplan–Meier analysis displaying the cumulative probability
of not reaching the outcome measure of intensive care unit admission
(left box) or mechanical ventilation (right box) for patients according to
tertiles of serum CRP levels at admission into the emergency department.
The solid line represents <28mg/L, the dense dotted line 28–69mg/L,
and the thin dotted line 70mg/L.
LB2398 Mass spectrometry-based high throughput resequencing
of 2009 inﬂuenza A (H1N1) virus
J. Gooskens °, C. Posthuma, J.C. Zevenhoven-Dobbe, E. Claas,
A. Kroes, E. Snijder (Leiden, NL)
Objectives: The 2009 pandemic inﬂuenza A (H1N1) virus contains novel
gene segments from zoonotic-origin and lacks numerous genetic markers
associated with increased virulence and antiviral resistance. The use
of mass spectrometry (MS)-based comparative sequence analysis was
investigated for high throughput determination of viral sequences and
detection of mutations.
Methods: During the ﬁrst 2009 pandemic wave (June 15 through
August 31), respiratory specimens obtained from febrile patients with
acute respiratory tract infection were tested by inﬂuenza A real-time
PCR. Novel inﬂuenza A (H1N1) virus sequences were monitored
for speciﬁc mutations or single nucleotide polymorphisms (SNPs)
associated with antiviral resistance (NA gene positions 119, 136, 155,
248/266, 274, 294), potential virulence factors (PB2 positions 271,
627, 701; PB1F2 position 66; NS1 position 92), and protein truncation
(PB1-F2 positions 12, 58, 88; NS1 position 220) using MS-based
comparative sequence analysis (Sequenom MassARRAY®/iSEQ™) and
regular cycle sequencing. In addition, follow-up specimens from three
immunocompromised patients with an acquired H275Y mutation in the
NA gene were tested. MS-derived sequences were compared to regular
cycle sequencing results.
Results: Inﬂuenza A virus was detected in 84/453 (19%) specimens.
Primers for novel inﬂuenza A (H1N1) were speciﬁc, as no product could
be ampliﬁed from occasional isolates of seasonal inﬂuenza A (H1N1)
or A (H3N2). A high concordance was observed between MS-based
and regular cycle sequencing results (nucleotide sequences >99%,
SNPs >93%, total specimens ~90%). No mutations associated with
antiviral resistance, potential virulence factors and protein truncation
were detected during the ﬁrst pandemic wave. MS-based resequencing
detected an H275Y mutation in only 4 of 9 (44%) follow-up specimens
in two of three patients with an established acquired H275Y mutation
by regular cycle sequencing.
Conclusion: High throughput MS-based resequencing provided reliable
sequence results on specimens obtained during onset of infection.
Detecting mutants in clinical follow-up specimens could be limited by
a lower sensitivity of this method but this should be further evaluated.
LB2399 Panobacumab adjunctive immuno-therapy for
Pseudomonas aeruginosa hospital-acquired pneumonia
versus a cohort group
Q. Lu, A. Dugard, P. Eggimann, P.F. Laterre, E. Mercier, M. Wolff,
J. Chastre, E.J. Giamarellos-Bourboulis, V.C. Gafner °, H. Lazar,
E. Mus, A. Perez, M. Tamm (Paris, Limoges, FR; Lausanne, CH;
Brussels, BE; Tours, FR; Athens, GR; Berne, Basel, CH)
Objectives: To assess the efﬁcacy of Panobacumab, a fully human IgM
monoclonal antibody against P. aeruginosa serotype O11, by comparing
a phase IIa trial with a standard care cohort trial both in hospital acquired
pneumonia (HAP) caused by P. aeruginosa O11.
Methods: Demographics, outcome and survival of HAP including
Ventilator Associated Pneumonia (VAP) in patients either treated with
standard antimicrobial therapy in a retrospective cohort trial (CT) or
with adjunctive Panobacumab therapy during an open phase IIa trial
were compared. Both trials applied the same inclusion exclusion criteria
and the same trial period of 30 days.
Results: 17 patients with VAP/HAP (14/3) caused by P. aeruginosa
O11 were enrolled in a phase IIa trial (ITT population) and treated
with Panobacumab, 13 of them received the full treatment course of 3
infusions (PP population, 12 VAP, 1 HAP) and 4 patients received only
one infusion. In the cohort trial 14 patients (VAP/HAP: 12/2) treated
with standard antibiotic therapy were included.
The mean age and weight were 65.8 y (years) (SD 17.2) and 78.0 kg
(SD 22.1) in the PP, 67.8 y (SD 15.4) and 77.1 kg (SD 20.2) in the ITT
population and 51.8 y (SD 22.3) and 67.1 kg (SD 13.0) in the CT.
At the time of suspicion of pneumonia a mean APACHE II and CPIS
of 19.4 (13−33) and 8.7 (7−11) in the PP, 18.9 (13−33) and 8.5 (7−11)
in the ITT and 14.5 (2−24) and 7.5 (3−12) in the CT population were
observed.
Tracheostomy was present in 53.8% and 52.9% in the PP and ITT
populations and 38.4% in the CT.
The pneumonia was polymicrobial in 69.2%, 70.6% and 85.7% in the
PP, ITT and CT respectively.
Stay at ICU and hospital before diagnosis of pneumonia were similar in
the 3 groups.
All 13 patients that received 3 doses of Panobacumab achieved
resolution of pneumonia with only two relapsing during the study. Hence
85% achieved resolution and 15% recurrence at day 30. In the ITT group
64.7% of the pneumonia resolved, 11.8% recurred and 23.5% continued
while in the CT 57% resolved, 7% recurred and 34% continued.
Resolution of pneumonia occurred markedly earlier in the Panobacumab
trial (8.9 days, SD: 3.3) than in the cohort trial (15.3 days, SD: 9.5).
The expected mortality derived from APACHE II score was 31% and
32% in the PP and ITT population and 22% in the cohort group. All
patients who received 3 doses of Panobacumab survived, 18% died in
the ITT group while in the CT 21% mortality matched the predicted
mortality.
Conclusions: Treatment of VAP/HAP caused by P. aeruginosa O11
with 3 doses of Panobacumab resulted in 100% survival, with highest
pneumonia resolution (85%), and in a shorter time when compared with
patients under standard therapy. The results indicate that Panobacumab
may be effective in such life-threatening indication and warrants larger
controlled trials.
LB2400 Detection and characterization of mixtures of hepatitis C
virus (HCV) types
M. Holodniy °, R.S. Diaz, R.L. Mathis, P.M. Feorino, C. Loveday,
Z. Grossman, R. Kantor, Y.W. Tang, R.M. Lloyd Jr. (Palo Alto, US;
Sao Paulo, BR; Buford, US; Buckinghamshire, UK; Ramat Gan, IL;
Providence, Nashville, US)
Background: Response to approved treatments for Hepatitis C Virus
infection is worse with HCV genotype one (the most common genotype)
compared with other HCV genotypes. Genotype determination is routine
for clinical trials. Detection of mixtures is not currently available; it may
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be desirable to detect minor populations of HCV genotypes, since this
may impact response to therapy.
Methods: A 15-member virus panel was constructed from patient-
derived virus containing genotypes 1b, 2b & 3a, mixed at ratios
of 10:90, 30:70, 50:50; 30,000 HCVRNA copies/mL each. Ratio
targets were conﬁrmed by clonal analysis (n = 50 each). The panel was
blinded, randomized, genotyped and reported using the TRUGENE®
5′NC genotyping kit. TRUGENE® FASTA ﬁles were downloaded into
a novel reporting module, MixuTYPE™ and compared to the original
TRUGENE® genotype. A second MixuTYPE™ analysis was performed
on 63 patient genotypes previously genotyped by Vanderbilt University
Clinic. FASTA sequences obtained from testing with the TRUGENE®
5′NC genotyping assay were downloaded into the MixuTYPE™
reporting module and subsequent results were compared between the
two methods. A conﬁrmatory test was also run on these specimens using
either HCV Inno-LiPA or HCV Invader assays at Vanderbilt. Specimens
containing conﬁrmed mixtures of two different HCV TYPES were cloned
(n = 50) for complete characterization.
Results: The HCV TRUGENE 5′NC assay using the integrated
OpenGene® reporting system were correctly identiﬁed mixtures in
3 of 15 (20%) of the characterized mixture panel while MixuTYPE™
correctly identiﬁed 15 of 15 from TRUGENE® FASTA sequences. The
correctly identiﬁed genotypes were all from the 1b/3a mixture panel
set at 30:70, 50:50 and 70:30 ratios. Sixty-three retrospective patient
specimen genotypes obtained by HCV TRUGENE® 5′NC assay were
sent for re-analysis of the original genotype using MixuTYPE™. No
mixtures were identiﬁed during the original testing while MixuTYPE™
identiﬁed mixtures in 5 of 63 (7%). Conﬁrmatory testing and subsequent
clonal analysis conﬁrmed MixuTYPE™ results in 5 of 5 samples.
Conclusions: HCV-infected patients may have mixed genotypes,
reﬂecting double infections. The ability to detect HCV genotype mixtures
may be of importance for treatment strategies (i.e. duration of treatment,
prognosis) and if future antivirals present differential response rates
according to genotypes.
